Revolutionary, minimally invasive long-term cardiac support device and mitral valve repair technology.

About us

Syntach AB is a Swedish innovation-driven company based in Lund, which has close links and extensive cooperation with various institutions at the University of Lund. The company was founded in 2012 with the aim of creating an entirely new class of cardiac support devices to improve the care of the rapidly-growing number of people with heart failure. Since many patients needing cardiac support also suffer from mitral valve regurgitation, (a leaking mitral valve), the company is also developing a minimally-invasive device to correct this to be used in combination with the cardiac support device, or on a standalone basis.

History

Syntach was founded in 2012 by Professor J.O. Solem from the University of Lund and Tor Peters, a Swedish entrepreneur based in Switzerland.


Jan Otto Solem, A well-known Scandinavian cardiac surgeon specializing in heart and lung transplantation and assist devices. Has worked with and implanted all the assist devices currently available.


Tor Peters, Main investor, co-founder of the Occlutech Group, with over 30 years’ experience in senior positions and board roles at various med-tech companies.


Background

There are only a few alternative long-term therapies available for end-stage heart failure patients, including implantable mechanical devices and heart transplantation. Both alternatives have limitations. Hearts for transplanting are significantly limited by the availability of donors, require expensive and complex heart surgery, and subsequent burdensome and expensive life-long immunosuppressive medication.


Currently available implantable mechanical heart pumps called LVADs are expensive and lead to a high risk of thrombosis due to their rapidly moving thrombogenic parts in the bloodstream, as well as bleeding due to anticoagulation medication. Furthermore, they require complex open-heart surgery which also has a drastic impact on recovery time. Additionally, infections frequently occur due to the opening through the skin for cable connection, and patients experience a lower quality of life due to the external power source of the implanted device.


To address these current challenges, Syntach is developing a medical device for the treatment of patients with chronic left ventricular heart failure. Our patented innovation is an entirely new approach to heart failure treatment and works by restoring the natural function of the mitral valve plane that is reduced in heart failure patients. By providing a novel and effective product that eliminates the limitations of current treatment alternatives such as invasiveness, high costs, significant infection risk, thrombosis risk, external batteries and significant energy consumption, Syntach will have a unique place on the market. With our Syntach Cardiac Support device – the Syntach CS – we aim to increase patient survival rates, improve the patients’ quality of life and reduce healthcare costs, meeting both clinical and socio-economic needs.


Innovation

Recent research at the University of Lund has enabled the underlying invention upon which Syntach was founded. Research has revealed the importance of the scooping movement of the mitral plane; two-thirds of the heart’s pumping function is generated by this movement, which is reduced in heart failure patients.


The invention is a fully implanted device, the Syntach CS. Instead of bypassing the left ventricle, like present LVADs do, the Syntach CS supports the mitral plane’s natural movement. This is an entirely new approach and it has several advantages.


The Syntach CS consists of a drive unit, a ring-shaped anchor implanted in the mitral plane, an additional anchor for the heart apex region and an implantable power unit. Electrical power is supplied by a fully implantable and rechargeable battery under the skin. The system also includes a smart wrist device to control the function and battery status of the Syntach CS. The mitral anchor will provide a means for simultaneous annuloplasty for patients who suffer heart failure and mitral insufficiency. Up to 45% of people who suffer from heart failure also suffer from mitral valve regurgitation and the device will be able to correct this.

Victoria Krüger

MSc, management board, Chief of RA/QA

Kristian Solem

MSc PhD, management board, Chief of IP, Chief of Research, HW/SW Manager

Jan Otto Solem

PhD MD, founder and member of the board, CEO

Daniel Engvall 

MSc, management board, CTO

Management board

Board of directors

Tor Peters

Founder and chairman of the board

Jan Otto Solem

PhD MD, Founder and member of the board, CEO

Syntach AB

Postal address: Box 4004, SE-227 21 Lund, Sweden
Visiting address: Traktorvägen 6C, SE-226 60 Lund, Sweden

+46 46 270 87 55
info@syntach.com

Syntach´s products are under development and not approved for clinical use.


© Syntach AB. All rights reserved. Privacy and cookie policy.
Designed and produced by Publiciteta&Co

OK

We use cookies to improve your experience. By using the site, you agree that cookies are used for this purpose. Please see our privacy policy for details.